The Effect of β-Carotene, Vitamin D3 and Zinc on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates

Sponsor
Indonesia University (Other)
Overall Status
Unknown status
CT.gov ID
NCT03366584
Collaborator
(none)
120
1
2
28.9
4.1

Study Details

Study Description

Brief Summary

Hyaline membrane disease, now commonly called respiratory distress syndrome (RDS), and feeding intolerance, which can lead to necrotizing enterocolitis (NEC), are two key morbidities found in premature neonates which resulted in high mortality rate in Indonesia. Cochrane meta-analysis proved that antenatal steroid therapy can reduce the morbidity and mortality rate of premature neonates. But there is still different outcomes and severity of disease in preterm newborn receiving the same dose of antenatal steroid therapy. This raises questions whether there are other factors influencing the development and maturity of lung and gut in preterm newborn, aside from steroid therapy. Vitamin A, D and zinc are already known for their function in fetal lung and gut development. To our best of knowledge, no study has evaluated the effect of these vitamins levels on HMD and feeding intolerance in premature neonates. Therefore, the aim of this study want to evaluate the effect of antenatal steroid therapy versus co-administered β-carotene, vitamin D3, zinc and antenatal steroid therapy on the presence and severity of HMD and feeding intolerance in premature neonates.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Beta carotene
  • Dietary Supplement: Vitamin D3
  • Dietary Supplement: Zinc
  • Drug: Dexamethasone
Phase 4

Detailed Description

This study is a randomized controlled trial and held in Cipto Mangunkusumo Hospital.

Pregnant women 28-34 weeks of gestational age, who fulfill the inclusion criteria, divide into two groups. Subjects from both groups receive the hospital protocol of preterm birth, 4 doses of 6 mg of dexamethasone, intravenous 12 hours apart to support lung maturation. Subjects in intervention group receive oral single-dose beta-carotene 25,000 IU, oral single-dose vitamin D3 50,000 IU and oral zinc 50 mg/day for 3 days. The maternal dan cord blood sample are obtained for zinc, vitamin A and 25(OH)D levels before and after intervention. After the premature neonates was born, observation will be done for maximum period of 4 weeks. The presence and severity of HMD and feeding intolerance or NEC will be recorded. Neonates showing any signs of HMD and/or abdominal distension will need to undergo additional chest/abdominal x-ray procedures.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
120 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The research will be held in Cipto Mangunkusumo General Hospital. Each participant of each group will be given dexamethasone 2x6 mg intravenous for 2 days which aims to support lung maturation followed by planned delivery within 1 week due to indication of maternal or fetal. The maternal dan cord blood sample are obtained for zinc, vitamin A and 25(OH)D levels examinations. Randomly, subjects will be divided into 2 groups which are group who is given the oral beta-carotene 25,000 IU, oral vitamin D3 50,000 IU and oral zinc 50 mg/day for 3 days, and group who is not given the intervention. After the premature neonates was born, observation will be done for maximum period of 4 weeks. The presence and severity of HMD and feeding intolerance or NEC will be recorded.The research will be held in Cipto Mangunkusumo General Hospital. Each participant of each group will be given dexamethasone 2x6 mg intravenous for 2 days which aims to support lung maturation followed by planned delivery within 1 week due to indication of maternal or fetal. The maternal dan cord blood sample are obtained for zinc, vitamin A and 25(OH)D levels examinations. Randomly, subjects will be divided into 2 groups which are group who is given the oral beta-carotene 25,000 IU, oral vitamin D3 50,000 IU and oral zinc 50 mg/day for 3 days, and group who is not given the intervention. After the premature neonates was born, observation will be done for maximum period of 4 weeks. The presence and severity of HMD and feeding intolerance or NEC will be recorded.
Masking:
Single (Outcomes Assessor)
Masking Description:
The neonates outcomes, hyaline membrane disease and feeding intolerance, will be assessed for maximum period of 4 weeks by doctor who in charge in NICU. They are outside the research team and blind to maternal treatment allocation.
Primary Purpose:
Prevention
Official Title:
The Effect of Co-administered β-Carotene, Vitamin D3, Zinc and Antenatal Steroid Therapy on Hyaline Membrane Disease and Feeding Intolerance in Premature Neonates
Actual Study Start Date :
Jan 1, 2017
Anticipated Primary Completion Date :
Dec 1, 2018
Anticipated Study Completion Date :
Jun 1, 2019

Arms and Interventions

Arm Intervention/Treatment
Experimental: Intervention

beta carotene 25,000 IU vitamin D3 50,000 IU zinc 50 mg dexamethasone 6 mg

Dietary Supplement: Beta carotene
Beta carotene 25,000 IU

Dietary Supplement: Vitamin D3
Vitamin D3 50,000 IU
Other Names:
  • Cholecalciferol
  • Dietary Supplement: Zinc
    Zinc 50 mg
    Other Names:
  • Zinc picolinate
  • Drug: Dexamethasone
    Dexamethasone 6 mg

    Active Comparator: Control

    dexamethasone 6 mg

    Drug: Dexamethasone
    Dexamethasone 6 mg

    Outcome Measures

    Primary Outcome Measures

    1. Hyaline membrane disease [1,5 years]

      The presence and severity of RDS (HMD) will be noted, according to chest X-ray result

    Secondary Outcome Measures

    1. Feeding Intolerance [1,5 years]

      The presence and severity of necrotican enterocolitis will be noted, according to abdominal x-ray result

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    17 Years to 45 Years
    Sexes Eligible for Study:
    Female
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Pregnant women who has preterm birth in 28-34 weeks gestational age
    Exclusion Criteria:
    • Multiple pregnancy

    • Drug allergy

    • Fetal congenital malformation

    • Maternal gestational diabetes mellitus

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cipto Mangunkusumo General Hospital Jakarta DKI Jakarta Indonesia 12440

    Sponsors and Collaborators

    • Indonesia University

    Investigators

    • Study Chair: Yuyun Lisnawati, Persahabatan General Hospital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Yuyun Lisnawati, dr, Indonesia University
    ClinicalTrials.gov Identifier:
    NCT03366584
    Other Study ID Numbers:
    • 190/2016
    First Posted:
    Dec 8, 2017
    Last Update Posted:
    Aug 13, 2018
    Last Verified:
    Aug 1, 2018
    Individual Participant Data (IPD) Sharing Statement:
    Undecided
    Plan to Share IPD:
    Undecided
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 13, 2018